Article Text


M272 Estimated Cost And Payment By Results (pbr) Tariff Reimbursement For Idiopathic Pulmonary Fibrosis Services Across 14 Specialist Providers In England
  1. C Hill1,
  2. R Nasr2,
  3. MI Fisher2,
  4. T Maher3,
  5. M Spiteri4,
  6. M Allen4,
  7. S Birring5,
  8. H Parfrey6,
  9. RK Hoyles7,
  10. M Gibbons8,
  11. G Burge9,
  12. J Scullion10,
  13. E Adams11,
  14. M Wickremasinghe12
  1. 1MAP BioPharma Limited, Cambridge, UK
  2. 2InterMune UK and Ireland Limited, London, UK
  3. 3Interstitial Lung Disease Unit, Royal Brompton Hospital, London, UK
  4. 4UHNS NHS Trust, Stoke-on-Trent, UK
  5. 5King’s College Hospital, London, UK
  6. 6Papworth Hospital, Cambridge, UK
  7. 7Churchill Hospital, Oxford, UK
  8. 8Royal Devon and Exeter Hospital, Exeter, UK
  9. 9Heartlands Hospital, Birmingham, UK
  10. 10Glenfield Hospital, Leicester, UK
  11. 11Aquarius Population Health Limited, Bristol, UK
  12. 12Imperial College NHS Healthcare Trust


Background Idiopathic Pulmonary Fibrosis (IPF) is an increasingly important respiratory illness in the UK. Rising prevalence of disease, emerging treatments, development of clinical guidelines for diagnosis and management and a NHS England service specification1 increase demands on healthcare providers who are required to enhance capacity or reconfigure services to manage patients.

Aims Estimate the patient care pathways across service providers in England compared with pathways recommended by NICE guidelines2 and the NHS England Service Specification; in terms of time and cost per patient by ‘diagnosis’, ‘management’ and ‘monitoring’, and then levels of reimbursement to providers for current levels of care and those recommended.

Methods Structured interviews with clinicians and coders ascertained current levels of service provision, excluding drug costs, by 14 NHS specialist ILD providers. Data were analysed utilising a bottom-up costing approach to estimate the total pathway costs. Comparison with services and costs as recommended by NICE guidelines and service specification allowed estimation of NHS providers’ profit or loss.

Results The estimated mean cost per patient for the first year of diagnosis, management and monitoring was £1,414, which is approximately £418 (42%) more than is reimbursed by the PBR tariff.3 By comparison, the equivalent cost of the NICE/service specification pathway is approximately £477 (41%) more than reimbursed by the tariff. In particular, it was noted that significant staff time is required for MDT discussion, but that this is not reimbursed.

Conclusions Results suggest that current NHS tariffs for ILD are insufficient to support current service provision. This is true for current levels of care as well as for the levels of care recommended by NICE. The risks of failure to amend the NHS tariff are:

  1. Incomprehensive diagnosis and management may adversely impact patient care and outcomes, at a time when services are under increasing scrutiny and disease prevalence is rising

  2. Adverse impact on the financial viability of specialist ILD providers





Abstract M272 Figure 1

Mean cost and reimbursement for 9 providers included in this study (range as black bars), and for the cost recommended by NICE guidelines and draft NHS England Service Specification

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.